Author + information
- Received June 28, 2004
- Revision received October 18, 2004
- Accepted October 25, 2004
- Published online April 19, 2005.
- Alexandra J. Lansky, MD, FACC⁎,
- Ricardo A. Costa, MD⁎,
- Michael Mooney, MD, FACC†,
- Mark G. Midei, MD, FACC‡,
- Henry K. Lui, MD, FACC§,
- Warren Strickland, MD, FACC∥,
- Roxana Mehran, MD, FACC⁎,
- Martin B. Leon, MD, FACC⁎,
- Mary E. Russell, MD, FACC¶,
- Stephen G. Ellis, MD, FACC#,
- Gregg W. Stone, MD, FACC⁎,⁎ (, )
- TAXUS-IV Investigators
- ↵⁎Reprint requests and correspondence:
Dr. Gregg W. Stone, Cardiovascular Research Foundation, 55 East 59th Street, 6th Floor, New York, New York 10022.
Objectives We sought to determine whether gender influences the results of paclitaxel-eluting stent implantation.
Background The TAXUS-IV trial demonstrated the safety and effectiveness of the slow-release, polymer-based, paclitaxel-eluting TAXUS stent compared to bare-metal stents in patients undergoing elective coronary intervention. Whether these results are generalizable to women is not known.
Methods A total of 1,314 patients with coronary lesions 10- to 28-mm long in 2.5- to 3.75-mm vessels were randomized to TAXUS stent versus bare-metal EXPRESS stents (Boston Scientific Corp., Natick, Massachusetts). Outcomes examined were stratified by gender.
Results A total of 662 patients (including 187 women) were assigned to the TAXUS stent, and 652 (180 women) received the control stent. Women were older than men, and had more hypertension, diabetes, renal insufficiency, unstable angina, and heart failure, but less smoking. Among patients receiving the TAXUS stent, women compared with men had higher unadjusted one-year rates of target lesion revascularization (TLR) (7.6% vs. 3.2%, p = 0.03), though female gender was not an independent predictor of TLR (odds ratio [OR] = 1.72 [95% confidence interval (CI) 0.68 to 4.37], p = 0.25). Moreover, restenosis rates were similar in men and women treated with the TAXUS stent (8.6% vs. 7.6%, respectively, p = 0.80), as was late loss (0.22 vs. 0.23 mm, p = 0.90). Compared to control stents, treatment with the TAXUS stent in women resulted in a significant reduction in nine-month restenosis (8.6% vs. 29.2%, p = 0.0001) and one-year TLR (7.6% vs. 14.9%, p = 0.02). The only independent predictor of freedom from restenosis in women was randomization to the TAXUS stent (OR = 0.28 [95% CI 0.11 to 0.74], p = 0.01).
Conclusions The benefits of the paclitaxel-eluting stent in reducing clinical and angiographic restenosis are generalizable to women.
- Received June 28, 2004.
- Revision received October 18, 2004.
- Accepted October 25, 2004.
- American College of Cardiology Foundation